[Lower risk myelodysplastic syndrome patients with transfusion dependent treated by dose-reduced decitabine].

@article{Fang2013LowerRM,
  title={[Lower risk myelodysplastic syndrome patients with transfusion dependent treated by dose-reduced decitabine].},
  author={Bao-zhi Fang and Zhen-zhen Liu and Guang-sheng He and Miao Miao and Xiang Wang and Hui-ying Qiu and Zheng-ming Jin and Xiao-wen Tang and Yue Han and Zheng-zheng Fu and Xiao Ma and Ai-ning Sun and Depei Wu and Chang-geng Ruan},
  journal={Zhonghua yi xue za zhi},
  year={2013},
  volume={93 40},
  pages={
          3189-92
        }
}
OBJECTIVE To evaluate the efficacy and safety of dose-reduced decitabine for the lower risk myelodysplastic syndrome (MDS) patients with transfusion dependent. METHODS Twenty-five cases of lower risk (low or intermediate-1 risk in IPSS risk group) MDS patients with transfusion dependence from November 2009 to September 2012 were treated by dose-reduced decitabine (20 mg/m(2) intravenously once daily for 3 days). And their efficacy, side effects, quality-of-life and survival rate were… CONTINUE READING